Bionano Genomics, Inc. (NASDAQ:BNGO) Given Average Recommendation of “Hold” by Analysts

Bionano Genomics, Inc. (NASDAQ:BNGO) has been given a consensus rating of “Hold” by the four brokerages that are covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $7.00.

BNGO has been the topic of a number of recent analyst reports. HC Wainwright initiated coverage on Bionano Genomics in a report on Wednesday, April 9th. They set a “buy” rating and a $10.00 target price on the stock. Wall Street Zen lowered Bionano Genomics from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Scotiabank boosted their price target on Bionano Genomics from $1.00 to $4.00 and gave the company a “sector perform” rating in a research note on Wednesday, April 2nd.

Bionano Genomics Price Performance

NASDAQ:BNGO opened at $3.40 on Friday. The company has a quick ratio of 1.34, a current ratio of 1.70 and a debt-to-equity ratio of 0.07. The firm has a market capitalization of $11.42 million, a price-to-earnings ratio of -0.02 and a beta of 2.20. Bionano Genomics has a twelve month low of $2.68 and a twelve month high of $41.10. The stock’s 50 day moving average price is $3.58 and its two-hundred day moving average price is $5.42.

Bionano Genomics (NASDAQ:BNGO) last posted its earnings results on Wednesday, May 14th. The company reported ($1.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.49) by $2.34. The business had revenue of $6.46 million for the quarter, compared to analyst estimates of $6.25 million. Bionano Genomics had a negative return on equity of 125.75% and a negative net margin of 294.05%.

Institutional Trading of Bionano Genomics

Several institutional investors have recently added to or reduced their stakes in the company. Everstar Asset Management LLC bought a new stake in Bionano Genomics in the 1st quarter valued at $126,000. Jane Street Group LLC bought a new stake in shares of Bionano Genomics during the 4th quarter valued at $118,000. XTX Topco Ltd bought a new stake in shares of Bionano Genomics during the 4th quarter valued at $45,000. Renaissance Technologies LLC bought a new stake in shares of Bionano Genomics during the 4th quarter valued at $46,000. Finally, Geode Capital Management LLC lifted its position in shares of Bionano Genomics by 13.0% during the 4th quarter. Geode Capital Management LLC now owns 997,676 shares of the company’s stock valued at $288,000 after acquiring an additional 114,822 shares during the period. 11.35% of the stock is currently owned by institutional investors.

About Bionano Genomics

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.